🔗 Visit the ClinicalTrials.gov page for NCT01506271
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. | Clin Infect Dis | 2013 | 4.07 |
| 2 | New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. | Antimicrob Agents Chemother | 2013 | 1.47 |
| 3 | New β-Lactamase Inhibitors in the Clinic. | Infect Dis Clin North Am | 2016 | 0.89 |
| 4 | Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy? | Expert Opin Pharmacother | 2016 | 0.89 |
| 5 | Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection. | Antimicrob Agents Chemother | 2016 | 0.75 |
| 6 | Pipeline of Known Chemical Classes of Antibiotics. | Antibiotics (Basel) | 2013 | 0.75 |